Citadel Advisors
NWBO

Citadel Advisors’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Citadel Advisors’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-17,627
Closed -$10K – 8429
2016
Q3 		$10K Buy
+17,627
New +$8.06K ﹤0.01% 7146
2016
Q1 		– Sell
-38,499
Closed -$76K – 9310
2015
Q4 		$123K Buy
38,499
+20,661
+116% +$99.3K ﹤0.01% 6465
2015
Q3 		$111K Buy
+17,838
New +$167K ﹤0.01% 6865
2015
Q2 		– Sell
-11,805
Closed -$103K – 9539
2015
Q1 		$87K Buy
11,805
+3,501
+42% +$23.6K ﹤0.01% 6961
2014
Q4 		$44K Buy
8,304
+1,569
+23% +$8.03K ﹤0.01% 7296
2014
Q3 		$34K Sell
6,735
-21,924
-76% -$135K ﹤0.01% 7151
2014
Q2 		$192K Buy
28,659
+16,669
+139% +$106K ﹤0.01% 5612
2014
Q1 		$87K Buy
+11,990
New +$71.1K ﹤0.01% 6333

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
CDH
Charles D. Hyman $1.79B AUM 17.18% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
MBT
Montecito Bank & Trust Santa Barbara, California $668M AUM 24.84% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BW
Biegel & Waller Columbia, Maryland $179M AUM 1.6% 1-Year Est. Return
MPI
Mairs & Power Inc St Paul, Minnesota $9.79B AUM 20.6% 1-Year Est. Return

Citadel Advisors's NWBO Position: Q4 2016 in Review

Citadel Advisors sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2016, closing a stake of 17,627 shares — an estimated $10K sold.

Citadel Advisors first reported a position in NWBO in Q1 2014 and held it in 8 quarters. The position peaked at $192K in Q2 2014. 8 funds tracked by Wall St. Rank hold NWBO as of Q4 2016.

  • Citadel Advisors reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2016 after selling out during the quarter.
  • Citadel Advisors sold 17,627 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2016, an estimated $10K.
  • Citadel Advisors first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q1 2014 and held it in 8 quarters.
  • Citadel Advisors's Northwest Biotherapeutics, Inc. Common stock position peaked at $192K in Q2 2014.
  • 8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2016.

Based on Citadel Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.